scholarly journals Fatigue as a symptom of neurological diseases

2021 ◽  
Vol 38 (2) ◽  
pp. 37-44
Author(s):  
T. V. Baidina ◽  
T. I. Kolesova ◽  
Yu. V. Malinina ◽  
T. N. Trushnikova ◽  
M. A. Danilova
Keyword(s):  
Neurological Diseases ◽  
Recovery Period ◽  
Brain Diseases ◽  
Severity Scale ◽  
Fatigue Syndrome ◽  
Impact Scale ◽  
The Central Nervous System ◽  
Fatigue Severity ◽  
Organic Brain ◽  
Fatigue Impact Scale

Objective. The aim of the work was to study the fatigue syndrome in various organic brain diseases. Materials and methods. Patients in the recovery period of hemispheric stroke, with Parkinson's disease and multiple sclerosis were examined. Along with the clinical one, there was conducted a study using the asthenia questionnaire MFI-20, FIS (Fatigue Impact Scale), FSS (Fatigue Severity Scale). Results. It has been established that patients with various diseases of the central nervous system have a syndrome of fatigue, which is a nosogenic one, that is, a consequence of organic brain damage.

Psychometric properties of the Fatigue Severity Scale and the Modified Fatigue Impact Scale

2013 ◽  
Vol 331 (1-2) ◽  
pp. 102-107 ◽  
Author(s):  
Y.C. Learmonth ◽  
D. Dlugonski ◽  
L.A. Pilutti ◽  
B.M. Sandroff ◽  
R. Klaren ◽  
...  
Keyword(s):  
Psychometric Properties ◽  
Fatigue Severity Scale ◽  
Severity Scale ◽  
Impact Scale ◽  
Fatigue Severity ◽  
Fatigue Impact Scale

A longitudinal study on effects of a six-week course for energy conservation for multiple sclerosis patients

2008 ◽  
Vol 14 (4) ◽  
pp. 500-505 ◽  
Author(s):  
C. Sauter ◽  
K. Zebenholzer ◽  
J. Hisakawa ◽  
J. Zeitlhofer ◽  
K. Vass
Keyword(s):  
Multiple Sclerosis ◽  
Sleep Quality ◽  
Energy Conservation ◽  
Fatigue Severity Scale ◽  
Severity Scale ◽  
Fatigue Management ◽  
Impact Scale ◽  
Fatigue Severity ◽  
Fatigue Impact Scale

Objective Fatigue management and energy conservation are effective strategies to minimize fatigue in multiple sclerosis (MS). Sustained results have not yet been reported. Methods A fatigue management course was provided for 32 MS patients. They were tested prior to, directly after participation in the course and in a 7—9 month follow-up with the Fatigue Severity Scale, the MS-specific Fatigue Scale, the Modified Fatigue Impact Scale (MFIS), the Pittsburgh Sleep Quality Index and a self-rating scale for depression. The Expanded Disability Status Score (EDSS) and the MS functional composite (MSFC) were evaluated before and after participation in the course. Results The total score and the Cognitive and Physical subscores of the MFIS showed significant improvements on both points of time. Scores in the Fatigue Severity Scale, MS-specific Fatigue Scale and Psychosocial Fatigue Impact Scale did not improve significantly. MS functional composite and EDSS remained unchanged after six weeks of course participation. Subjective sleep quality improved directly after participation in the course and after 7—9 months. The depression score decreased significantly to a normal level at the end of training and in the 7—9 month follow-up. Conclusion Fatigue management enables MS patients to cope with their fatigue and energy more effectively. Follow-up evaluations showed stable results after 7—9 months. Multiple Sclerosis 2008; 14: 500—505. http://msj.sagepub.com

scholarly journals Diagnosis of sleepiness, fatigue and depression in patients with myasthenia gravis

2020 ◽  
Vol 10 (4) ◽  
pp. 27-37
Author(s):  
O. A. Kreis ◽  
T. M. Alekseeva ◽  
Yu. V. Gavrilov ◽  
P. O. Valko ◽  
Yu. Valko
Keyword(s):  
Myasthenia Gravis ◽  
Excessive Daytime Sleepiness ◽  
Daytime Sleepiness ◽  
Fatigue Severity Scale ◽  
Severity Scale ◽  
Impact Scale ◽  
Fatigue Severity ◽  
Autoimmune Comorbidity ◽  
Fatigue Impact Scale ◽  
The Impact

Introduction. Examination of excessive daytime sleepiness, fatigue and depression in patients with myasthenia gravis is important for differential diagnosis of other disorders, and adds to a comprehensive clinical assessment.Objective. The aim is a comprehensive assessment of sleepiness, fatigue and depression and evaluation of the impact of autoimmune comorbidity on these symptoms in myasthenia gravis patients, using newly validated Russian versions of international questionnaires. The present article aims at familiarizing a wider Russian-speaking audience of specialists in the field of neuromuscular disease and sleep medicine with the main findings of our previously published work.Materials and methods. The study included 73 patients with MG and 230 control subjects. For sleepiness, fatigue and depression evaluation were used: Fatigue Severity Scale (FSS), Fatigue Impact Scale (FIS) (cognitive / physical / psychosocial subscales), Epworth Sleepiness Scale (ESS), Beck Depression Inventory (BDI) (cognitive-affective and somatic domains), Spielberger–Khanin State Trait Anxiety Inventory (STAI).Results. The Fatigue Severity Scale and Fatigue Impact Scale showed good psychometric properties and can be used to identify distinct aspects of fatigue in patients with myasthenia gravis. The studied patient cohort revealed clinically significant fatigue (69.9 %), excessive daytime sleepiness (15.1 %), moderate to severe depression (20.5 %), a high level of personal (64.4 %) and situational anxiety (27.4 %). Among 13 patients with myasthenia gravis and additional autoimmune comorbidity, there were no significant differences in the severity of sleepiness, fatigue and depression compared with the main group.Conclusion. The use of self-reported scale of sleepiness, fatigue and depression combined with careful clinical-neurological characterization adds to a more comprehensive view of the patient. The identification of sleepiness, fatigue and depression can guide therapeutic decisions and contributes to a better patient care. The presence of concomitant autoimmune pathology in patients with myasthenia gravis does not seem to increase the severity of sleepiness, fatigue and depression.

scholarly journals Poor Sleep in Multiple Sclerosis Correlates with Beck Depression Inventory Values, but Not with Polysomnographic Data

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Christian Veauthier ◽  
Gunnar Gaede ◽  
Helena Radbruch ◽  
Klaus-Dieter Wernecke ◽  
Friedemann Paul
Keyword(s):  
Multiple Sclerosis ◽  
Beck Depression Inventory ◽  
Pittsburgh Sleep Quality Index ◽  
Poor Sleep ◽  
Severity Scale ◽  
Analog Scale ◽  
Impact Scale ◽  
Fatigue Severity ◽  
Fatigue Impact Scale ◽  
The Relationship

Objectives. Pittsburgh Sleep Quality Index (PSQI) values correlate with depression, but studies investigating the relationship between PSQI values and polysomnographic (PSG) data showed inconsistent findings.Methods. Sixty-five consecutive patients with multiple sclerosis (MS) were retrospectively classified as “good sleepers” (GS) (PSQI ≤ 5) and “poor sleepers” (PS) (PSQI > 5). The PSG data and the values of the Visual Analog Scale (VAS) of fatigue, Modified Fatigue Impact Scale (MFIS), Fatigue Severity Scale (FSS), Epworth Sleepiness Scale (ESS), and the Beck Depression Inventory (BDI) were compared.Results. No significant differences were found either for PSG data or for ESS, MFIS, and FSS values; but PS showed significantly increased BDI and VAS values.Conclusions. Poor sleep is associated with increased depression and fatigue scale values.

scholarly journals Treatment of Fatigue in Multiple Sclerosis Patients: A Neurocognitive Approach

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Mauro Catalan ◽  
Alessandra De Michiel ◽  
Alessio Bratina ◽  
Susanna Mezzarobba ◽  
Lorella Pellegrini ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Motor Planning ◽  
Rehabilitation Program ◽  
Severity Scale ◽  
Impact Scale ◽  
Disability Status ◽  
Neurocognitive Rehabilitation ◽  
Fatigue Severity ◽  
Fatigue Impact Scale ◽  
Multiple Sclerosis Patients

The objective of the study was to treat fatigue in patients with multiple sclerosis (MS) by a neurocognitive rehabilitation program aimed at improving motor planning by using motor imagery (MI). Twenty patients with clinically definite MS complaining of fatigue were treated for five weeks with exercises of neurocognitive rehabilitation twice a week. Patients were evaluated by Fatigue Severity Scale (FSS), Modified Fatigue Impact Scale (MFIS), MSQoL54, Expanded Disability Status Scale (EDSS), and MS Functional Composite (MSFC). After treatment, a decrease in fatigue was detected with both FSS () and MFIS (). MSFC () and MSQoL54 () scores improved compared to baseline. At six-month followup, the improvement was confirmed for fatigue (FSS, ; MFIS ) and for the physical subscale of MSQoL54 (). No differences in disability scales were found. These results show that neurocognitive rehabilitation, based on MI, could be a strategy to treat fatigue in MS patients.

Validation of the Russian version of the Fatigue Impact Scale and Fatigue Severity Scale in multiple sclerosis patients

2018 ◽  
Vol 138 (5) ◽  
pp. 408-416 ◽  
Author(s):  
Yury V. Gavrilov ◽  
Galina G. Shkilnyuk ◽  
Philipp O. Valko ◽  
Igor D. Stolyarov ◽  
Elena V. Ivashkova ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Fatigue Severity Scale ◽  
Severity Scale ◽  
Russian Version ◽  
Impact Scale ◽  
Fatigue Severity ◽  
Fatigue Impact Scale ◽  
Multiple Sclerosis Patients

Pharmacologic Therapy for Multiple Sclerosis–Related Fatigue

2005 ◽  
Vol 7 (1) ◽  
pp. 22-27 ◽  
Author(s):  
Jay H. Rosenberg
Keyword(s):  
Multiple Sclerosis ◽  
Sleep Disturbances ◽  
Well Being ◽  
Pharmacologic Therapy ◽  
Controlled Trials ◽  
Common Symptom ◽  
Impact Scale ◽  
Moderate Fatigue ◽  
The Central Nervous System ◽  
Fatigue Severity

Fatigue is the most common symptom of multiple sclerosis and is perhaps the symptom with the most devastating impact on patient well-being. It is reported by 75% to 95% of individuals, and more than half describe it as the worst symptom of the disease. The mechanisms underlying the development of fatigue remain unclear; although fatigue is believed to be a primary symptom of MS (ie, related to the demyelinating processes of the disease), fatigue may also occur secondarily to factors such as sleep disturbances, depression, or the effects of medications. The highly variable presentation of MS and the number of agents used for disease modification and symptom management make it important for potential contributors to MS-related fatigue to be identified and managed appropriately. If fatigue continues despite elimination or adequate management of secondary causes, pharmacologic therapy may be required. Several agents have been reported to improve MS-related fatigue; however, only three have been investigated in controlled trials. Amantadine has been studied in several small controlled trials, and appears to be effective in one quarter to one third of those with mild-to-moderate fatigue. It has shown efficacy on a number of scales, including the Visual Analog Scale for Fatigue (VAS-F) and the MS-Specific Fatigue Scale (MS-FS). The central nervous system (CNS) stimulant pemoline has demonstrated limited benefit in clinical trials and is often poorly tolerated, especially in higher doses. Recently, the wake-promoting agent modafinil has been shown to significantly improve MS-related fatigue on a number of commonly used fatigue assessment scales, including the Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS).

Evaluation of the Modified Fatigue Impact Scale in four different European countries

2005 ◽  
Vol 11 (1) ◽  
pp. 76-80 ◽  
Author(s):  
D Kos ◽  
E Kerckhofs ◽  
I Carrea ◽  
R Verza ◽  
M Ramos ◽  
...  
Keyword(s):  
Psychometric Properties ◽  
Intraclass Correlation ◽  
European Countries ◽  
Cronbach’S Alpha ◽  
Cronbach's Alpha ◽  
Cognitive Subscale ◽  
Impact Scale ◽  
Definite Multiple Sclerosis ◽  
Fatigue Severity ◽  
Fatigue Impact Scale

Objective: To evaluate the psychometric properties of the Modified Fatigue Impact Scale (MFIS) in four different European countries. Methods: Individuals with definite multiple sclerosis (MS) were selected from centres in Italy (n=50), Spain (n=30), Slovenia (n=50) and Belgium (n=51) and completed the MFIS and the Fatigue Severity Scale (FSS) twice (interval ≤ 3 days). Results: In all four samples, the MFIS demonstrated a good reproducibility (intraclass correlation coefficient ≥ 0.84), with no significant differences between countries (P=0.77). Moderate correlations were found between the MFIS and FSS. No significant correlations were found between the MFIS and age, gender, type of MS, duration of the disease or EDSS score. Factor analysis of all samples (n=181) could not completely confirm the original assumptions concerning the physical, cognitive and psychosocial component. The total score, the physical and the cognitive subscale of the scale were homogeneous (Cronbach’s alpha 0.92, 0.88 and 0.92, respectively), but the psychosocial subscale had a Cronbach’s alpha of 0.65. Conclusions: No cultural or linguistic differences were found in the psychometric properties of the Belgian, Italian, Slovenian or Spanish version of the MFIS. We recommend this scale for research purposes and in clinical practice. Due to the limited value of the psychosocial subscale, we recommend interpreting this subscale with caution.

Validation of the NARCOMS Registry: fatigue assessment

2005 ◽  
Vol 11 (5) ◽  
pp. 583-584 ◽  
Author(s):  
Ruth Ann Marrie ◽  
Gary Cutter ◽  
Tuula Tyry ◽  
Olympia Hadjimichael ◽  
Denise Campagnolo ◽  
...  
Keyword(s):  
Construct Validity ◽  
Convergent Validity ◽  
Disease Duration ◽  
Research Committee ◽  
The North ◽  
Impact Scale ◽  
Fatigue Severity ◽  
Fatigue Impact Scale ◽  
American Research ◽  
Registry Report

Participants in the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry report disability using Performance Scales (PS), which assess eight domains. We aimed to validate the PS fatigue subscale (PSF) using the Fatigue Severity Scale (FSS) and the Modified Fatigue Impact Scale (MFIS) as external criteria. We measured correlations between the PSF and age, disease duration and PS subscales to assess construct validity. The PSF correlated strongly with the MFIS (r=0.72, p<0.0001) and FSS (r=0.75, p<0.0001). Correlations between the PSF and age, disease duration were low, indicating divergent validity. Correlations between the PSF and spasticity, sensory and mobility PS scales were moderate, indicating convergent validity. The PSF has adequate criterion and construct validity in MS.

Sign in / Sign up

Export Citation Format

Share Document